The number of class action lawsuits filed against Pozen after its MT-100 migraine headache drug was rejected by the FDA continues to grow.

The following firms have filed the lawsuits since Pozen announced the FDA’s decision last Monday:

  • Paskowitz & Associates

  • Brodsky & Smith LLC

  • Brian M. Felgoise, P.C.

  • Charles J. Piven, P.A.

  • Brian M. Felgoise, P.C.

  • Charles J. Piven, P.A.
  • Pozen (Nasdaq: POZN) stock closed down 7 cents on Monday at $5.73. It hit a 52-week low of $5.40 after the FDA news after trading as high as $19.40 just a few months ago.

    Pozen: www.Pozen.com